logo
Plus   Neg
Share
Email

Vaxart: OWS To Test Oral COVID-19 Vaccine Candidate In Non-Human Primates

Vaxart, Inc. said its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by the U.S. Government's Operation Warp Speed. The study is designed to demonstrate the efficacy of the oral COVID-19 vaccine candidate.

Andrei Floroiu, Chief Executive Officer of Vaxart Inc., said: "Our vaccine is a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns."

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT